Comprehensive CHB Testing: Quantitative & Qualitative HBsAg and Beyond

Description

This session will explore the clinical significance of comprehensive biomarker testing in chronic hepatitis B (CHB), focusing on how quantitative and qualitative HBsAg, HBeAg, and HBV DNA testing can help offer more personalized care to CHB patients by characterizing disease phases, supporting better-informed treatment decisions, and improving monitoring strategies.

Industry Supporter: GSK